Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Aytu Biopharma (AYTU) over the last 12 years, with Q4 2025 value amounting to $6.0 million.

  • Aytu Biopharma's Cost of Revenue rose 1035.88% to $6.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $21.7 million, marking a year-over-year decrease of 55.33%. This contributed to the annual value of $20.9 million for FY2025, which is 532.99% down from last year.
  • Per Aytu Biopharma's latest filing, its Cost of Revenue stood at $6.0 million for Q4 2025, which was up 1035.88% from $5.3 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Cost of Revenue high stood at $13.9 million for Q1 2021, and its period low was $4.8 million during Q2 2025.
  • Moreover, its 5-year median value for Cost of Revenue was $7.0 million (2023), whereas its average is $8.3 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 59721.75% in 2021, then tumbled by 5820.06% in 2024.
  • Over the past 5 years, Aytu Biopharma's Cost of Revenue (Quarter) stood at $10.8 million in 2021, then decreased by 2.46% to $10.6 million in 2022, then plummeted by 50.59% to $5.2 million in 2023, then grew by 4.16% to $5.4 million in 2024, then grew by 10.36% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q4 2025, $5.3 million for Q3 2025, and $4.8 million during Q2 2025.